To include your compound in the COVID-19 Resource Center, submit it here.

Allozyne, Poniard deal

Allozyne will reverse-merge with cancer company Poniard in a stock deal. Allozyne stockholders will own about 65% of the merged company, while Poniard stockholders

Read the full 241 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE